Needham initiated coverage of Evolent Health (EVH) with a Buy rating and $15 price target Evolent is a leading value-based care enabler, providing solutions for payors and providers to succeed across primary and specialty care, the analyst tells investors. While the stock has seen a steep selloff following Q3 earnings, the issues were common in the end market and the firm believes the company is taking the “right steps to remedy the headwinds,” the analyst added.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health appoints Von Nguyen as Chief Medical Officer
- Evolent Health price target lowered to $15 from $45 at JPMorgan
- Evolent Health price target lowered to $28 from $34 at Oppenheimer
- Evolent Health management to meet with Oppenheimer
- Evolent Health price target lowered to $21 from $33 at Citi